Working…
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma (FUSIONMM-003)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02807454
Recruitment Status : Active, not recruiting
First Posted : June 21, 2016
Last Update Posted : January 31, 2020
Sponsor:
Information provided by (Responsible Party):
Celgene

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : July 5, 2020
Estimated Study Completion Date : July 5, 2020